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Abstract: The prosperity of a country is closely related to its level of education to fuel research and innovation. Doctor-
al graduates have attained the highest education level and should be the key players in research and innovation. The 
number of doctoral graduates is increasing rapidly in most/many countries, but is less well correlated to changes in 
prosperity of a country.  
The innovative medicines initiative (IMI) was established to help Europe strengthen its position in biomedical research 
and development. During its planning stage IMI observed large gaps in the scientific interaction between academia and 
industry in Europe, and that undergraduate students were not realizing the career opportunities within biomedical R&D. 
A major objective for the education and training section of IMI, the European Medicines Research Training Network 
(EMTRAIN, http://www.emtrain.eu), has therefore been to work out a framework for public private partnership PhD 
(PPP-PhD) and to create a cohort of networking, industry-aware scientists. 
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1. Introduction 
he prosperity of a country is closely related to 
its level of education to fuel research and in-
novation[1–3]. Doctoral graduates have attained 
the highest education level and should be the key 
players in research and innovation. In most European 
universities, the number of doctoral graduates by far 
exceeds the number of tenured academic positions. 
The situation in the USA is similar and has led to the  
suggestion of the need to “rethink some fundamental 
features of the US biomedical research ecosystem[4]”. 
The European Science Foundation (ESF) is running a 
pilot study to provide up-to-date information about 
career tracking of doctorate holders in Europe to aid 
policy makers[5]. There has been an increasing realiza-
tion that the education of a PhD student should also 
include career coaching that extends beyond the tradi-
tional academic community and training in transfer-
able skills. In recent years, a number of programs have  
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been developed to support career transitions for PhDs. 
In addition to these formal programs, there are nu-
merous online services, books and articles that focus 
exclusively on the non-academic path[6]. In December 
2014, a joint statement on doctoral training[7] included, 
“Doctoral candidates should be offered the opportuni-
ty to acquire additional methodological competences 
as well as transversal, soft and generic skills helpful 
for careers in science, the wider science-based job 
market and in the job market outside of science. Doc-
toral candidates select such offers on their own choice.” 
These modifications to the PhD education have been 
important steps forward to improve the interaction 
between academia and society. Still, much remains to 
be done before society can fully take advantage of the 
resources used for the highest level of education.  
The field of drug discovery and development is an 
excellent example of an area that can gain tremend-
ously from a close interaction between academia and 
industry in the training of PhD students. The pharma-
ceutical industry is dependent on substantial invest-
ments in research and development. The Innovative 
Medicines Initiative (IMI)[8] was established to help 
Europe strengthen its position in biomedical research 
and development. During its planning stage, IMI ob-
served large gaps in the scientific interaction between 
academia and industry in Europe, and that under-
graduate students were not realizing the career oppor-
tunities within biomedical R&D. This was partly due 
to the lack of understanding about how the industry 
worked, career options and collaborations, and intel-
lectual property and publication strategies, which had 
been exacerbated by the previous, outdated “fee for 
service” model for industry-academia partnerships. A 
major objective for the education and training section 
of IMI, the European Medicines Research Training 
Network (EMTRAIN), has therefore been assigned to 
work out a framework for public private partnership 
PhD (PPP-PhD) and to create a cohort of networking, 
industry-aware scientists.  
To obtain a well-substantiated basis for a more for-
malized PPP-PhD programme in medicines, we have 
interviewed eight large European-based biopharma-
ceutical companies. All companies unanimously de-
clared that the major driving force to operate PPP- 
PhD programmes would be to build scientific relations 
to academic research centres of excellence. Other im-
portant factors were recruitment of outstanding stu-
dents, possibility to arrange PhD opportunities for 
employees and generation of co-authored publications 
in top-ranked scientific journals. All companies em-
phasized the importance of presenting the student with 
pre-competitive projects. The number of ongoing 
PPP-PhD programmes was relatively limited, but the 
over-all impression was that they are an asset and a 
potential investment for the company. The industries 
with the most extensive PPP-PhD programmme are 
located in the UK and in Denmark. Both countries 
have well developed routines for national support to 
PPP-PhD programme. The pharmaceutical companies 
Novo Nordisk and Lundbeck have been extensively 
involved in the Danish Industrial PhD programme[9] 
which has now been running for more than 30 years 
and resulted in higher number of patent applications 
and increased gross profit for the participating compa-
nies. The PPP-PhD graduates spend 50% of the PhD 
time in the company and earn about 10% more than 
conventional PhD students. Very few experience long- 
term unemployment and they are three times more 
likely to hold leadership or senior scientist positions in 
the company than conventional PhDs. The universities 
have welcomed this supply of highly qualified and 
motivated students and the programme has increased 
the national competitiveness for both industry and 
academia[10].  
The concept of PPP-PhD programmes is not new, 
but a combination of increased industry awareness, 
involvement of new academic and industry partners 
and student networking would represent a consider-
able advantage. A larger scale implementation of PPP- 
PhD programmes in the field of medicine will how-
ever require changes in attitude from both academia 
and industry. The academic society may worry about 
the prospect to have to perform more applied and less 
basic science, and the industrial body may feel that 
academia is still pursuing the ivory tower philosophy 
to be disconnected from the practical concerns of 
everyday life. Mutual understanding and interaction 
are keys to success. Since changes of attitude are best 
implemented via the young generation, we have in-
vited students from existing PPP-PhD programmes to 
participate in a series of workshops hosted by the in-
dustry and organized in collaboration with representa-
tives from academia. We now have experience from 4 
workshops, hosted by AstraZeneca in 2012, GlaxoS-
mithKline in 2013, UCB in 2014 and Janssen in 2015. 
The 2016 workshop will be hosted by Bayer.  
The attendance has been limited to approximately 
26 students to promote interaction and networking. 
The vast majority of the students are enrolled in ex-
Anita Aperia, Jorgen Dirach, Mike Hardman, et al. 
 
 Journal of Medicines Development Sciences (2015)–Volume 1, Issue 2 39 
isting PPP-PhD programs, but only a few students 
from universities that do not have existing PPP-PhD 
programmes are invited and selected on a competitive 
basis. A faculty consisting of staff members from bio-
pharmaceutical companies and universities attended 
the entire meeting. The topics are selected to boost the 
interaction between academia and industry, promote 
networking and provide future perspectives on drug 
discovery. Examples of themes are: future directions 
in the field of drug discovery, importance of multidis-
ciplinary research, interaction with academia, entre-
preneurship in action, activities in emerging countries 
and role of in-house discoveries. All students are 
asked to give a short oral presentation of their research 
project. These presentations have provided an impres-
sive exposé of what can be accomplished when the 
collaboration between industry and academia is en-
hanced by the joint responsibility of a talented young 
PhD student. So far a total of 107 students have par-
ticipated, representing 22 countries, 56 universities 
and 17 companies. The student feedback has been ex-
cellent: 98% gave the workshop a good or very good 
overall opinion; more than 95% stated that their awa-
reness of drug industry had increased and 100% said 
that they would recommend the workshop to others. 
An important spin-off effect has been that the student 
participants have continued to stay in contact and now 
forming a network of future industry- aware scientists. 
2. PPP-PhD Framework 
Based on the information from the interviews with the 
industrial partners and the workshops, we have set up 
a proposal for a PPP-PhD framework, where the work-
shops, with their proven capacity to promote net-
working, are a cornerstone (Figure 1).   
Based on the workshop experience, and in consulta-
tion with academic and industry supervisors as well as 
PhD students, a competency profile for industry-aware 
PhDs is being developed. The high-level topic list is 
shown in Figure 2. The profile will provide guidance 
for PhDs students to facilitate working in both the 
academic and the industry setting. 
In order to help students identify suitable PhD trai-
ning posts, the on-course® database[11] includes a sec-
tion on such opportunities, and on courses (university 
or private providers) that might help them acquire the 
appropriate knowledge to support their training. 
 
 
1. The PhD programme will roughly follow the Bologna process. National considerations have to be taken into ac-
count. 
2. The PhD programme will usually include 3.5–4 years of training. The PhD thesis should correspond to 3–4 years of 
research written up as a single monograph or as published papers in accordance with university guidelines. Pub-
lication of papers in peer-reviewed journals is encouraged*. Details on the format of publications should be cov-
ered by the PhD contract. 
3. The EMTRAIN PhD student will have two supervisors; the main supervisor will be active in academia and the 
co-supervisor in industry. 
4. The EMTRAIN PhD student will spend a minimum of 3 months in industry and remaining time working on a re-
search project in an academic environment. This will promote mobility between industry and academia. 
5. The EMTRAIN PhD student is recommended to attend courses, visit other laboratories and attend international 
meetings and workshops in accordance with the university requirements. One such event could be the annual 
EMTRAIN PhD Workshop. This will promote mobility across countries. EMTRAIN supports the use of the Bologna 
process for PhD training where courses or other learning activities corresponding to 30 ECTS credit points is 
recommended.  
6. The EMTRAIN PhD student should take a minimum of three EMTRAIN recommended core courses. One course 
should be on Drug Development. The remaining courses should be selected from a list of topics recommended by 
EMTRAIN. It is suggested that at least one course is taken abroad. 
 
*in some universities this is mandatory 
 
 
Figure 1. The EMTRAIN joint (Public Private Partnership) PhD framework. 
 
 
1. Knowledge and understanding 
2. Personal proficiency and aptitude 
3. Research management and organisation 




Figure 2. Competency profile – high-level topics. 
Once they have received their PhD degree, they can 
maintain their professional development by further 
knowledge acquisition (via on-course®) and by tran-
sforming the learning into practical applications via 
further competence development[12]. 
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3. Conclusion 
The process of implementation of a PPP-PhD fra-
mework, to be incorporated as a branch of the univer-
sity´s PhD training programme, has now been initiated. 
All universities that have had students participating in 
the workshop have been contacted. So far the proposal 
has been met with a very positive attitude. A key 
question is: who will be financially responsible for the 
PPP-PhD programme in drug development? We pro-
pose that economic responsibility should be shared 
between industry, university and national or EU funds, 
because it will serve the purpose to strengthen the 
sense of common responsibility and it will be a highly 
rewarding long-term investment for all partners. Fur-
thermore, we would like to encourage each company 
to set up a PhD students’ coordination office in order 
to help strengthen the links with academic partners 
and to facilitate the integration of students within the 
company, and make them feel that they belong to a 
"dynamic and agile science PPP sharing community". 
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